Madrigal Pharmaceuticals, Inc. vs Eli Lilly & Co.
MDGL vs LLY — side-by-side comparison from reported financials. MDGL leads 3, LLY leads 6 of 9 comparable metrics.
Madrigal Pharmaceuticals, Inc.
MDGL · Healthcare
$471.75-1.08%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | MDGL | LLY |
|---|---|---|
| Price | $471.75 | $1 177.20 |
| Market cap | $10.9B | $1.05T |
| Revenue (TTM) | $1.28B | $79.7B |
| Revenue growth | +149.0% | +31.7% |
| Net margin | -25.3% | 33.5% |
| Free cash flow | -$207M | $18.2B |
| Net cash (debt) | $644M | ($35.2B) |
| 1-year price return | +10.1% | +37.6% |
| P/E | — | 41.6 |
| P/E vs own history (cheap-side %) | — | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -57% | 93% |
| Altman Z-score | 7.49 | 7.10 |
| CV checks passed | 5 of 9 | 11 of 9 |
| Employees | 915 | 50,000 |
Full résumé-style profiles: MDGL CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.